Status | Study |
Not yet recruiting |
Study Name: Efficacy of Bone Marrow Mesenchymal Stem Cell in Pulmonary Hemosiderosis Condition: Idiopathic Pulmonary Hemosiderosis Date: 2016-12-03 Interventions: Biological: Bone marrow mesenchymal stem cells in treatment of Idiopathic pulmonary hemosiderosis |
Not yet recruiting |
Study Name: Florbetaben as an Amyloid Plaque Marker in Elderly Patients With Focal or Disseminated Superficial Hemosiderosis Condition: Amyloid Cerebral Angiopathy Alzheimer Disease Date: 2016-01-19 Interventions: Device: Pet scan with FBB |
Recruiting |
Study Name: Confounder-Corrected Quantitative MRI Biomarker of Hepatic Iron Content Condition: Iron Overload Hemochromatosis Hemosi Date: 2013-12-12 Interventions: Other: MRI R2 MRI scan Other Name: Magnetic Resonanc |
Withdrawn |
Study Name: Treatment of Iron Overload Requiring Chelation Therapy Condition: Transfusional Iron Overload Iron Overload Iron Chelation Date: 2013-08-20 Interventions: Drug: SPD602 32, 50 or 75 mg/k |
Enrolling by invitation |
Study Name: A Case Control Study to Evaluate the Cognitive and Brain Function of β-thalassemia Patients. Condition: Thalassemia Brain Function (Measured by ERP Level) Date: 2013-08-07 |
Completed |
Study Name: Pharmacogenetic Study in Patients Received Iron Chelating Agent Condition: Hemosiderosis Date: 2012-06-12 |
Completed |
Study Name: Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload Condition: Beta-thalassemia Major Sickle Cell Disease Iron Date: 2012-01-06 Interventions: Drug: DFP (ferriprox) and deferasirox (ICL 670) |
Completed |
Study Name: Non-invasive Quantification of Liver Iron With MRI Condition: Iron Overload Hemosiderosis Date: 2011-08-17 Interventions: Device: Non-contrast MRI Non-contrast MRI will be performed on each subject, at both 1.5T and 3.0T. Diff |
Completed |
Study Name: Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox Condition: Transfusional Hemosiderosis Date: 2011-07-12 Interventions: Drug: deferasirox Other Name: ICL670 |
Completed |
Study Name: Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO). Condition: Sickle Cell Disease Date: 2010-03-15 Interventions: Drug: ICL670 Daily doses of ICL670 were taken orally 30 minutes before breakfast. The doses range from 5 |